Results 71 to 80 of about 3,958 (169)

A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients

open access: yes, 2006
A new C18 reversed-phase column and UV HPLC method for the detection of mitotane, its principal metabolites, dichlorodiphenylacetate and dichlrodiphenylethene, and its precursor DDT is described.
DAFFARA F   +9 more
core  

Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma [PDF]

open access: yes, 2018
Context Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce.
Quinkler, Marcus   +23 more
core   +1 more source

Prediction of anticancer peptides derived from the true lectins of Phoenix dactylifera and their synergetic effect with mitotane

open access: yesFrontiers in Pharmacology
Background and aims: Cancer continues to be a significant source of both illness and death on a global scale, traditional medicinal plants continue to serve as a fundamental resource of natural bioactive compounds as an alternative source of remedies ...
Othman Baothman   +10 more
doaj   +1 more source

Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma - Mitotane monitoring and tumor regression

open access: yes, 2015
Purpose: To define a mitotane dose for pediatric patients with adrenocortical cancer (ACC) that maintains therapeutic plasma levels (TL) between 14 and 20 mu g/mL and to verify its antitumor efficacy in association with 8 cycles of cisplatin, etoposide ...
Santana, MHA   +11 more
core   +1 more source

Walsh & Hoyt: Mitotane

open access: yes, 2005
Mitotane (o,p\u27-DDD) is a direct adrenal suppressant that is used in the treatment of inoperable adrenal cortical ...
Mark L. Moster, MD; Rod Foroozan, MD
core  

A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma

open access: yes
Adrenocortical carcinomas (ACCs) are rare and aggressive malignancies of adrenal cortex, associated with largely unknown mechanisms of biological development and poor prognosis.
Fabiano Flauto   +5 more
core   +1 more source

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens

open access: yesFrontiers in Microbiology, 2018
Due to limited new antibiotics, polymyxins are increasingly used to treat multidrug-resistant (MDR) Gram-negative bacteria, in particular carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.
Thien B. Tran   +9 more
doaj   +1 more source

Pharmacokinetic variability of mitotane in pediatric adrenocortical carcinoma and the role of CYP2B6 genotypes: a pediatric case series

open access: yesEJC Paediatric Oncology
Despite therapeutic drug monitoring of mitotane, achieving target plasma concentrations remains challenging. Commonly reported enzymes involved in mitotane metabolism are cytochrome P450 (CYP)3A4 and 2B6, with CYP2B6 being highly polymorphic.
Ivy A.E. Ankone   +10 more
doaj   +1 more source

Effect of mitotane in patients with ectopic adrenocorticotropic hormone syndrome caused by advanced pancreatic neuroendocrine tumors: a case series and review of the literature

open access: yesJournal of International Medical Research
Ectopic adrenocorticotropic hormone syndrome (EAS) is a rare condition caused by pancreatic neuroendocrine tumors (p-NETs). The severe hypercortisolemia that characterizes EAS is associated with a poor prognosis and survival.
Shaobo Hu   +6 more
doaj   +1 more source

Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells: Mitotane-induced cytochrome c oxidase defect [PDF]

open access: yes, 2014
Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p'-DDD) is the most effective medical therapy for adrenocortical carcinoma but its molecular mechanism of action remains poorly understood.
Paci, Angelo   +11 more
core   +2 more sources

Home - About - Disclaimer - Privacy